Proteasome activator subunit 3 promotes pancreatic cancer growth via c-Myc-glycolysis signaling axis

Cancer Letters

Volumn 386, Issue , 2017, Pages 161-167

  Guo, Jiefang ^a   Hao, Jun ^a   Jiang, Hongxue ^a   Jin, Jing ^a   Wu, Hongyu ^a   Jin, Zhendong ^a   Li, Zhaoshen ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

c Myc; Glycolysis; Pancreatic cancer; PSME3

Indexed keywords

MYC PROTEIN; PEPTIDES AND PROTEINS; PROTEIN PSME3; UNCLASSIFIED DRUG; AUTOANTIGEN; KI ANTIGEN; MYC PROTEIN, HUMAN; PROTEASOME;

ADULT; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER PROGNOSIS; CANCER STAGING; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE SILENCING; GLYCOLYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PSME3 GENE; SIGNAL TRANSDUCTION; TUMOR INVASION; TUMOR VOLUME; AGED; CELL MOTION; ENZYMOLOGY; GENETIC TRANSFECTION; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; PANCREAS TUMOR; PATHOLOGY; PROTEIN STABILITY; RNA INTERFERENCE; TIME FACTOR; TUMOR CELL LINE;

AGED; AUTOANTIGENS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; GLYCOLYSIS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN STABILITY; PROTEOLYSIS; PROTO-ONCOGENE PROTEINS C-MYC; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION; TUMOR BURDEN;

EID: 85002368664     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2016.08.018     Document Type: Article

References (31)

1. [1] Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics, 2016. CA Cancer J. Clin. 66 (2016), 7–30.
2. [2] Ma, C.P., Slaughter, C.A., DeMartino, G.N., Identification, purification, and characterization of a protein activator (PA28) of the 20 S proteasome (macropain). J. Biol. Chem. 267 (1992), 10515–10523.
3. [3] Mao, I., Liu, J., Li, X., Luo, H., REGgamma, a proteasome activator and beyond?. Cell Mol. Life Sci. 65 (2008), 3971–3980.
4. [4] Tanahashi, N., Yokota, K., Ahn, J.Y., Chung, C.H., Fujiwara, T., Takahashi, E., et al. Molecular properties of the proteasome activator PA28 family proteins and gamma-interferon regulation. Genes Cells 2 (1997), 195–211.
5. [5] Li, X., Lonard, D.M., Jung, S.Y., Malovannaya, A., Feng, Q., Qin, J., et al. The SRC-3/AIB1 coactivator is degraded in a ubiquitin- and ATP-independent manner by the REGgamma proteasome. Cell 124 (2006), 381–392.
6. [6] Liu, J., Yu, G., Zhao, Y., Zhao, D., Wang, Y., Wang, L., et al. REGgamma modulates p53 activity by regulating its cellular localization. J. Cell Sci. 123 (2010), 4076–4084.
7. [7] Ali, A., Wang, Z., Fu, J., Ji, L., Liu, J., Li, L., et al. Differential regulation of the REGgamma-proteasome pathway by p53/TGF-beta signalling and mutant p53 in cancer cells. Nat. Commun., 4, 2013, 2667.
8. [8] Chen, X., Barton, L.F., Chi, Y., Clurman, B.E., Roberts, J.M., Ubiquitin-independent degradation of cell-cycle inhibitors by the REGgamma proteasome. Mol. Cell. 26 (2007), 843–852.
9. [9] Chai, F., Liang, Y., Bi, J., Chen, L., Zhang, F., Cui, Y., et al. REGgamma regulates ERalpha degradation via ubiquitin-proteasome pathway in breast cancer. Biochem. Biophys. Res. Commun. 456 (2015), 534–540.
10. [10] Murata, S., Kawahara, H., Tohma, S., Yamamoto, K., Kasahara, M., Nabeshima, Y., et al. Growth retardation in mice lacking the proteasome activator PA28gamma. J. Biol. Chem. 274 (1999), 38211–38215.
11. [11] Barton, L.F., Runnels, H.A., Schell, T.D., Cho, Y., Gibbons, R., Tevethia, S.S., et al. Immune defects in 28-kDa proteasome activator gamma-deficient mice. J. Immunol. 172 (2004), 3948–3954.
12. [12] He, J., Cui, L., Zeng, Y., Wang, G., Zhou, P., Yang, Y., et al. REGgamma is associated with multiple oncogenic pathways in human cancers. BMC Cancer, 12, 2012, 75.
13. [13] Wang, X., Tu, S., Tan, J., Tian, T., Ran, L., Rodier, J.F., et al. REG gamma: a potential marker in breast cancer and effect on cell cycle and proliferation of breast cancer cell. Med. Oncol. 28 (2011), 31–41.
14. [14] Zhang, M., Gan, L., Ren, G.S., REGgamma is a strong candidate for the regulation of cell cycle, proliferation and the invasion by poorly differentiated thyroid carcinoma cells. Braz J. Med. Biol. Res. 45 (2012), 459–465.
15. [15] Roessler, M., Rollinger, W., Mantovani-Endl, L., Hagmann, M.L., Palme, S., Berndt, P., et al. Identification of PSME3 as a novel serum tumor marker for colorectal cancer by combining two-dimensional polyacrylamide gel electrophoresis with a strictly mass spectrometry-based approach for data analysis. Mol. Cell Proteomics 5 (2006), 2092–2101.
16. [16] Wang, H., Bao, W., Jiang, F., Che, Q., Chen, Z., Wang, F., et al. Mutant p53 (p53-R248Q) functions as an oncogene in promoting endometrial cancer by up-regulating REGgamma. Cancer Lett. 360 (2015), 269–279.
17. [17] Tian, M., Xiaoyi, W., Xiaotao, L., Guosheng, R., Proteasomes reactivator REG gamma enchances oncogenicity of MDA-MB-231 cell line via promoting cell proliferation and inhibiting apoptosis. Cell Mol. Biol. (Noisy-le-grand) 55 (2009), OL1121–1131.
18. [18] Guo, J., Gao, J., Li, Z., Gong, Y., Man, X., Jin, J., et al. Adenovirus vector-mediated Gli1 siRNA induces growth inhibition and apoptosis in human pancreatic cancer with Smo-dependent or Smo-independent Hh pathway activation in vitro and in vivo. Cancer Lett. 339 (2013), 185–194.
19. [19] Cai, J., Guan, H., Fang, L., Yang, Y., Zhu, X., Yuan, J., et al. MicroRNA-374a activates Wnt/β-catenin signaling to promote breast cancer metastasis. J. Clin. Invest. 123 (2013), 566–579.
20. [20] Finley, L.W., Zhang, J., Ye, J., Ward, P.S., Thompson, C.B., SnapShot: cancer metabolism pathways. Cell Metab., 17, 2013 466–466.
21. [21] Shim, H., Dolde, C., Lewis, B.C., Wu, C.S., Dang, G., Jungmann, R.A., c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc. Natl. Acad. Sci. U. S. A. 94:13 (1997 Jun 24), 6658–6663.
22. [22] Miller, D.M., Thomas, S.D., Islam, A., Muench, D., Sedoris, K., c-Myc and cancer Metabolism. Clin. Cancer Res. 18 (2012), 5546–5553.
23. [23] Dang, C.V., Le, A., Gao, P., MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin. Cancer Res. 15 (2009), 6479–6483.
24. [24] Bustamante, E., Pedersen, P.L., High aerobic glycolysis of rat hepatoma cells in culture: role of mitochondrial hexokinase. Proc. Natl. Acad. Sci. U. S. A. 74 (1977), 3735–3739.
25. [25] Frey, P.A., The Leloir pathway: a mechanistic imperative for three enzymes to change the stereochemical configuration of a single carbon in galactose. FASEB J. 10 (1996), 461–470.
26. [26] Wu, Y., Wang, L., Zhou, P., Wang, G., Zeng, Y., Wang, Y., et al. Regulation of REGgamma cellular distribution and function by SUMO modification. Cell Res. 21 (2011), 807–816.
27. [27] Shi, Y., Luo, X., Li, P., Tan, J., Wang, X., Xiang, T., Ren, G., miR-7-5p suppresses cell proliferation and induces apoptosis of breast cancer cells mainly by targeting REGgamma. Cancer Lett. 358 (2015), 27–36.
28. [28] Cantor, J.R., Sabatini, D.M., Cancer cell metabolism: one hallmark, many faces. Cancer Discov. 2 (2012), 881–898.
29. [29] Le, A., Rajeshkumar, N.V., Maitra, A., Dang, C.V., Conceptual framework for cutting the pancreatic cancer fuel supply. Clin. Cancer Res. 18 (2012), 4285–4290.
30. [30] Vander Heiden, M.G., Cantley, L.C., Thompson, C.B., Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324 (2009), 1029–1033.
31. [31] Zwaans, B.M., Lombard, D.B., Interplay between sirtuins, MYC and hypoxia-inducible factor in cancer-associated metabolic reprogramming. Dis. Model. Mech. 7 (2014), 1023–1032.